Oncology News | pharmaphorum

News

Syndax gets FDA okay for first-in-class leukaemia drug

A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.

News

MSD joins PD-1/VEGF push in cancer with LaNova deal

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.

News

Bone marrow aspirate showing the histologic correlate of multiple myeloma under the microscope, H&E stain

GSK hails survival data with revived myeloma drug Blenrep

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat

News

Metsera gets $215m for obesity trials, and other financings

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

News

Scrabble letters spelling out 'Learn from failure'

Daiichi and AZ pull Dato-DXd filing with FDA and try again

Nine months after filing their TROP2-directed antibody-drug conjugate Dato-DXd for a lung cancer indication with the FDA, Daiichi Sankyo and AstraZeneca have pulled the submission.

Syndax gets FDA okay for first-in-class leukaemia drug

MSD joins PD-1/VEGF push in cancer with LaNova deal

GSK hails survival data with revived myeloma drug Blenrep

Metsera gets $215m for obesity trials, and other financings

BioNTech buys Biotheus and its Keytruda rival for $950m

Daiichi and AZ pull Dato-DXd filing with FDA and try again

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks